alexa Cytotoxicity and Radiosensitization of High Grade Gliom
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Cytotoxicity and Radiosensitization of High Grade Glioma Cells by CI-1033, an Irreversible Pan-Erbb Inhibitor

Dannis G van Vuurden1,2*, Shruti Shukla1,2, Laurine E Wedekind1,2,3, Gitta K. Kuipers3, David P Noske2,4, W Peter Vandertop4, M Vincent M Lafleur3, Esther Hulleman1,2, ertjan JL Kaspers1, Jacqueline Cloos5
1Department of Pediatric Oncology / Hematology, VU University Medical Center, Amsterdam, The Netherlands
2Neuro-oncology Research Group, VU University Medical Center, Amsterdam, The Netherlands
3Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
4Neurosurgical Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
Corresponding Author : Dannis G van Vuurden, MD
Department of Pediatric Oncology/ Hematology
VU University Medical Center, PO Box 7057
1007 MB Amsterdam, the Netherlands
Tel: +31-20-444-2420
Fax: +31-20-444-2422
E-mail: [email protected]
Received May 07, 2013; Accepted June 09, 2013; Published June 12, 2013
Citation: van Vuurden DG, Shukla S, Wedekind LE, Kuipers GK, Noske DP, et al. (2013) Cytotoxicity and Radiosensitization of High Grade Glioma Cells by CI-1033, an Irreversible Pan-ErbB Inhibitor. J Cancer Sci Ther 5:249-255. doi: 10.4172/1948-5956.1000213
Copyright: © 2013 van Vuurden DG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Background: High-grade gliomas (HGG) are highly infiltrative malignancies, causing considerable mortality in child- and adulthood, necessitating new therapies. Novel therapies directed against multiple epidermal growth factor family (ErbB) members are potentially effective in HGG.

Aim: To assess ErbB family expression in normal brain and pediatric and adult HGG in silico and to determine radiosensitizing property of the pan-ErbB inhibitor CI-1033, in HGG cells in vitro.

Material and methods: In silico mRNA array expression analysis was performed to assess EGFR, ERBB2, ERBB3, ERBB4 gene expression in normal brain, adult and pediatric HGG. ErbB family protein expression was determined in HGG cell lines using Western blot. Sulforhodamine-B assay was used to assess cytotoxicity of CI- 1033 andclonogenic assays to determine radiosensitization. The effect on cell cycle distribution and PI3K-Akt/Ras- MAPK signalling of CI-1033 ± radiation was measured using flow cytometry.

Results: EGFR and ERBB2 were significantly overexpressed in datasets of pediatric and adult HGG. Heterogeneous protein expression of EGFR, ErbB2, 3 and 4 was observed in HGG cell lines. CI-1033 IC50 values of 1.0 μM, 2.5 μM and 4.3 μMwere found in D384MG, U-251 MG and Gli-6 cells, respectively. CI-1033 significantly sensitized Gli-6 and D384MGcells to radiation, with 24 and 48 hrs pre-treatment respectively.

Conclusion: EGFR and ErbB2 are overexpressed in adult and childhood HGG. Irreversible pan-ErbB inhibition by CI-1033 is cytotoxic and radiosensitizes HGG cell lines in vitro, warranting further in vivo studies.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version